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Background: A patient-centred approach with self-monitoring of blood glucose (SMBG) has emerged as the preferred approach
in monitoring and managing blood glucose. The success of SMBG in diabetes treatment and management relies heavily on the
accurate and reproducible measurement of blood glucose values.
Aim: To evaluate whether patients and healthcare professionals can accurately estimate blood glucose using photometric strips,
by visually matching them to colorimetric charts.
Methods: A cross-sectional study design was used with participants enrolled from patients and healthcare providers attending
and working at the Diabetes Clinic of Kalafong Provincial Tertiary Hospital (KPTH). A convenience sample of 144 patients and 10
healthcare professionals was enrolled.
Results: Limits of agreement of patient and healthcare professional visual estimates were 11.1 to 10.4 mmol/l and 6.7 to 5.7
mmol/l, respectively. The mean difference for estimates by healthcare professionals was 0.8 mmol/l (95% CI 1.30–0.31 mmol/
l) while patient estimates had a mean difference of 0.4 mmol/l (95% CI 1.2−0.5 mmol/l).
Conclusions: The study noted that visual colour matching was inexact and generally would overestimate blood glucose.
Healthcare professionals gave visual estimates that were more accurate in comparison with patients.
Keywords: colorimetric charts, glucometer, photometric strips, SMBG, visual estimates
Introduction
The prevalence and incidence of diabetes has been on the rise
globally, including in South Africa, and this trend is projected
to continue.1,2 In 2010, the global prevalence of diabetes
among adults in the age group 20–79 years was estimated to
be 6.4%, and by the year 2030 diabetes in the same age
group is projected to be 7.7%.3 In 2010, diabetes prevalence in
South Africa, despite the paucity of diabetes prevalence data,
was estimated to be 4.5% for adults aged between 20 and 79
years and is projected to affect 4.9% of this age group by
2030.3 This increasing trend of diabetes, previously viewed as
a Western ailment or a disease of the affluent, is becoming an
epidemic in Africa.4
The shift of diabetes to epidemic levels has been driven by
several factors, among them rapid urbanisation, obesity and
an increasing life expectancy. These factors are, among others,
leading to the phenomenon of epidemiologic transition as
described by Habib.5 Epidemiologic transition is characterised
by a shift in cause of morbidity and mortality from predomi-
nantly communicable diseases to non-communicable diseases.6
Communicable diseases in 1990 were responsible for 42% of
global mortality and in 2020 are projected to be responsible
for 17% of global mortality.5 Conversely, NCDs, which in 1990
were responsible for 47% of global mortality, are expected in
the year 2020 to be responsible for about 69% of global mor-
tality.5 South Africa is not exempt from this transition. Bradshaw
(2003) estimated that 51% of the deaths in South Africa in the
year 2000 were due to communicable diseases, HIV/AIDS inclus-
ive, with NCDs contributing 37% of total mortality.6 Statistics
South Africa (StatsSA) in its 2013 report on causes of mortality,
identified NCDs as the leading cause of mortality at 51.3% and
communicable diseases at 38.4% of total mortality.7 Evidently,
NCDs have become a leading cause of mortality globally and
in South Africa specifically, with diabetes, an NCD itself, contri-
buting to the high mortality figures.5,8
Diabetes is characterised by a hyperglycaemic state; hence, the
treatment and management of the disease focuses on control-
ling the blood glucose level of patients to near normal. The
target blood glucose interval for diabetic patients is between
4.0 and 10.0 mmol. Consequently, when blood glucose
exceeds 11 mmol, it is considered hyperglycaemic and, similarly,
when blood glucose falls below 4 mmol it presents hypoglycae-
mia. Both hyperglycaemia and hypoglycaemia present symp-
toms that are problematic and may lead to complications.
Chronic hyperglycaemia can contribute to organ damage and
failure.9 The organs mostly affected are eyes, kidneys, peripheral
nerves, heart and blood vessels.10 In the year 2000, diabetes was
responsible for about 4.3% of deaths recorded in South Africa.10
In the same year, diabetes also contributed to 14% of ischaemic
heart disease (IHD), 10% of stroke, 12% of hypertensive disease
and 12% of renal disease mortalities, which mostly affected
people aged 30 years and above.11–13 These numbers are evi-
dence of howmuch diabetes and its complications have contrib-
uted to the disease burden in South Africa, making treatment
and management a necessity.
The treatment and management of diabetes requires close
monitoring to prevent hyper- and hypoglycaemia. A patient-
centred approach, self-monitoring of blood glucose (SMBG),
has emerged as the preferred approach in the management
and care of diabetic patients on insulin therapy.1,14 Self-monitor-
ing of blood glucose (SMBG) empowers patients in the manage-
ment of diabetes. The patients thereby become actively
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I troduction: Atherosclerotic cardiovas ular dis ase is a major contributor to morbidity and mortality in diabetic patients. Strict
goal-directe lipid control in patients with diabetes is associ ted with better cardiovascular outcomes.
h main aim of this study i to escribe th lipid pr file of a cohort of pa ients with type 2 diabetes mellitus in order to
highlight the quality of lipid control by correlating the type and dose of lipid-modifying therapy used with lipid levels.
: retrospective analysis was performed on 200 type 2 diab tic patien s who attended the Charlotte Maxeke
Johannesburg Academic Hospital diabetic clinic. Their lip d pr files and the type a d dose of lipid-modify ng therapy
prescribed was assessed.
Although the majority of participants (146 [73%]) were at the de level for total cholesterol, fewer (133 [66.5%]) were
at the id al level for triglycerides and 112 (56%) participants were at th ideal level for HDL cholesterol, only 5 (26.5%)
participants were at target for LDL cholest rol, and very few, only 25 (12.5%), participants were at target for all four lipid
parameters.
Conclusion: Higher doses of statins or the u e of more potent statins with or with ut the addition of other lipid modifying
drugs is recommended in order to achieve LDL cholesterol target in the majority of patients with type 2 diabetes.
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Introduction
Type 2 diabetes mellitus is a met bolic disord r that results in
persistently higher than normal serum glu ose levels in
untreated patie ts.1 Long-term vascular complications r the
cause of poor outcomes, such as death and disability,2 with car-
di vascula disease being the major caus .3 Dyslipidaemia,
whic is an inde endent risk fact r for cardiovascu ar dise se
is pr ent in the majority of p tient with type 2 diabetes and
affects all lipid fractions.4
Elevated total a d LDL cholesterol (LDL-C) as well as elevated
levels of triglycerides together with low levels of HDL cholesterol
(HDL-C) are found in the majority of patients with type 2
diabetes.4
Redu ing LDL-C levels onfers signific nt protection against the
higher risk of cardiovascular and cerebrovascular complication
in dyslipidaemic patients.4 A redu tion in LDL-C by approxi-
mately 1 mmol/l d creases the five-year incidence of major cor-
onary events by approxim t ly 20%.5
HDL-C levels are also used as a marker of cardiovascular disease
risk with low levels being associated with a greater risk of cardi-
ovascular disease, independent of LDL-C levels.6,7
In addition, high triglyceride levels in both fasted and non-fasted
patients are also associated with a greater cardiovascular risk.8
Treatment of diabetic dyslipidaemia with statins (or HMG CoA
reductase inhibitors) has been shown to significantly reduce
adverse ca diovascular events and these are ther fore the
drugs of choice in this setting.2
Several tatins with differing potencies ar curren ly in us . For
example in the Collaborative Atorvastatin Diabetes Study
(CARDS) study a l w dose of atorvastatin (10 mg daily)
decr ased LDL-C by 40% and triglycerides by 19%.9 The Euro
Aspire studies revealed a reduction in total cho esterol levels
greater than 4.5 mmol/l from 94.5% to 46.2% attributable to
stati therapy.10
At maximal dose atorvastatin and rosuvastatin can p tentially
decrease LDL-C by as much as 60%.5
Another class of lipid-l wering th rapy called fibrates (or peroxi-
som prolifer tor-activated receptor-α agonists), in the form of
the drug ezetimibe, may be necessary to red ce LDL-C,
especially in p tients at high risk for car iovascular dise se.11
The role of other treatment options f r this purpose i still
u er investigation.
The combined use of a statin with a fibrate may be more ben-
eficial than statin therapy alone in patients with type 2 diabetes
and dyslipidaemia12 but this has not been clearly demonstrated
in cardiovascular outcome studies.13
Globally, poor control of diabetic dyslipidae ia remains a
problem and an unacceptably low proportion of patients
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The prevalence and incidence of diabetes has been on the rise
globally, including in South Africa, and this trend is projected
to continue.1,2 In 2010, the global prevalence of diabetes
among adults in the age group 20–79 years was estimated to
be 6.4%, and by the year 2030 diabetes in the same age
group is projected to be 7.7%.3 In 2010, diabetes prevalence in
South Africa, despite the paucity of diabetes prevalence data,
was estimated to be 4.5% for adults aged between 20 and 79
years and is projected to affect 4.9% of this age group by
2030.3 This increasing trend of diabetes, previously viewed as
a Western ailment or a disease of the affluent, is becoming an
epidemic in Africa.4
The shift of diabetes to epidemic levels has been driven by
several factors, among them rapid urbanisation, obesity and
an increasing life expectancy. These factors are, among others,
leading to the phenomenon of epidemiologic transition as
described by Habib.5 Epidemiologic transition is characterised
by a shift in cause of morbidity and mortality from predomi-
nantly communicable diseases to non-communicable diseases.6
Communicable diseases in 1990 were responsible for 42% of
global mortality and in 2020 are projected to be responsible
for 17% of global mortality.5 Conversely, NCDs, which in 1990
were responsible for 47% of global mortality, are expected in
the year 2020 to be responsible for about 69% of global mor-
tality.5 South Africa is not exempt from this transition. Bradshaw
(2003) estimated that 51% of the deaths in South Africa in the
year 2000 were due to communicable diseases, HIV/AIDS inclus-
ive, with NCDs contributing 37% of total mortality.6 Statistics
South Africa (StatsSA) in its 2013 report on causes of mortality,
identified NCDs as the leading cause of mortality at 51.3% and
communicable diseases at 38.4% of total mortality.7 Evidently,
NCDs have become a leading cause of mortality globally and
in South Africa specifically, with diabetes, an NCD itself, contri-
buting to the high mortality figures.5,8
Diabetes is characterised by a hyperglycaemic state; hence, the
treatment and management of the disease focuses on control-
ling the blood glucose level of patients to near normal. The
target blood glucose interval for diabetic patients is between
4.0 and 10.0 mmol. Consequently, when blood glucose
exceeds 11 mmol, it is considered hyperglycaemic and, similarly,
when blood glucose falls below 4 mmol it presents hypoglycae-
mia. Both hyperglycaemia and hypoglycaemia present symp-
toms that are problematic and may lead to complications.
Chronic hyperglycaemia can contribute to organ damage and
failure.9 The organs mostly affected are eyes, kidneys, peripheral
nerves, heart and blood vessels.10 In the year 2000, diabetes was
responsible for about 4.3% of deaths recorded in South Africa.10
In the same year, diabetes also contributed to 14% of ischaemic
heart disease (IHD), 10% of stroke, 12% of hypertensive disease
and 12% of renal disease mortalities, which mostly affected
people aged 30 years and above.11–13 These numbers are evi-
dence of howmuch diabetes and its complications have contrib-
uted to the disease burden in South Africa, making treatment
and management a necessity.
The treatment and management of diabetes requires close
monitoring to prevent hyper- and hypoglycaemia. A patient-
centred approach, self-monitoring of blood glucose (SMBG),
has emerged as the preferred approach in the management
and care of diabetic patients on insulin therapy.1,14 Self-monitor-
ing of blood glucose (SMBG) empowers patients in the manage-
ment of diabetes. The patients thereby become actively
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involved in setting their own glycaemic control targets and
achieving them.15 The success of SMBG in diabetes treatment
and management relies heavily on the accurate and reproduci-
ble measurement of blood glucose values.
Glucometers used in SMBG use one of two technologies to
measure blood glucose: reflectance photometry or electroche-
mical reactions.10,16 Reflectance photometry glucometers
make use of photometry strips that contain a chemically impreg-
nated test strip that reacts with blood glucose, resulting in a
colour change on the test strip.10,17 The resulting colour
change on the reflectance photometric strips may be inter-
preted using a digital glucometer to determine the blood
glucose level. Alternatively, the colour change can be visually
matched against a blood glucose concentration colorimetric
chart (on the glucometer strip container), to obtain a visual esti-
mate of blood glucose. Electrochemical glucometers make use
of electrochemical strips that contain ions which change con-
ductance as they react with blood glucose.17 The change in
the conductance of the ions is interpreted to give a blood
glucose reading by a glucometer.18 In South Africa, both tech-
nologies discussed above are in use to measure and monitor
blood glucose. However, there are a variety of other glucometers
in use, and the preference for device depends on technical per-
formance, affordability and availability of the devices among
other factors.19
Visually estimating blood glucose by colour matching photo-
metric strips to colorimetric charts remains convenient and
easy to use, in the absence of a photometric glucometer.
However, a major shortcoming of visually estimating blood
glucose using reflectance photometry strips is the ability to
accurately match the colour change with that on the colori-
metric charts.
Reflectance photometry strips make use of a colour change,
and visual matching interpretation requires good colour
vision and perception. Diabetic patients are susceptible to
vision impairments and this may compromise their ability to
perform visual matching accurately when using the visual esti-
mation for SMBG approach. The acceptable errors for gluc-
ometer readings set by the International Organisation for
Standardization (ISO) are less than approximately 20% for
measures greater than 4.2 mmol/l and less than approximately
0.83 mmol/l for measures less than 4.2 mmol/l.1 The accurate
visually estimated measurements should preferably also be in
compliance with the ISO standard.1 In a 1981 study by Clem-
ents et al., visual estimates of blood glucose using Chemstrips
showed strong correlation between visually estimated blood
glucose and the true glucose readings (r = 0.966); however, it
did not assess clinical relevance of the blood glucose
measures.20 Clinical relevance of blood glucose measures
obtained from different methods was assessed by Clarke
et al. in 1987, in a study that affirmed the usefulness of an
error grid.21 In the Clarke et al. study, visual blood glucose esti-
mates had 96.1% of the total readings in zones A and B of the
error grid, suggesting the technique is a highly accurate one,
largely giving clinically relevant measures.21 That study,
however, did not specify the number of participants who
gave the visual estimates but described them as laboratory per-
sonnel and patients. Given the impact of diabetes on eyesight
it is important to establish how well patients estimate blood
glucose visually. Earlier studies that have attempted to evaluate
the visual ability of patients to estimate blood glucose relied on
linear correlation. This study combined Bland–Altman plots and
Error Grid Analysis to assess visual ability applied to different
groups (healthcare providers and patients) for comparison.
This study examined the ability of diabetic patients and health-
care professionals to accurately interpret the colour change on a
reflectance photometric strip using colorimetric charts (printed
on the glucometer strip container) to estimate blood glucose.
The cost of glucometers is high and the availability of blood
glucose monitoring is significantly limited in lower income
populations. Currently no home glucose monitoring is available
for type 2 diabetic patients accessing primary health care in the
Tshwane district. This study attempted to evaluate the accuracy
of an alternative cheaper option of blood glucose monitoring
without using a glucometer.
Materials and methods
Study population and patient selection
The study was a cross-sectional study conducted at the Diabetes
Clinic of Kalafong Provincial Tertiary Hospital (KPTH), in Atterid-
geville, Pretoria. The study population was selected from
patients and healthcare providers attending and working in
the Kalafong Hospital Diabetes Clinic. The patients seen at the
clinic are adult outpatients, with type 1 or type 2 diabetes. In
terms of blood glucose control, the clinic has patients across
the spectrum from poorly controlled to well-controlled diabetic
patients. Convenience sampling was used to select study
participants.
Data collection
Patients on the clinic’s records attend scheduled appointments
at the clinic throughout the year. During these visits blood
glucose and the general well-being of the patient are noted.
The appointment list of the clinic allowed the investigator to
identify patients who met the inclusion criteria and, based on
that information, approach them to ask for their participation
in the study. Informed consent was obtained from all
participants.
Participating patients were asked to estimate their blood
glucose concentration by matching colour changes that
occurred on photometric strips, Accu-Chek® Active strips
(Roche Diabetes Care, Burgess Hill, UK), to a colorimetric
chart. The healthcare professional attending to them would
also visually estimate the patient’s blood glucose. The pro-
cedure for the collection of visual estimates was as follows:
first, the healthcare professional placed a sample of blood
from a patient’s pricked finger onto the photometric strip.
Second, the strip was inserted into a reflective photometric
glucometer, Accu-Chek®, by the investigator who recorded
the blood glucose reading on the glucometer. The patient
and the healthcare professional were blinded from the actual
blood glucose measured by the glucometer. Third, for visual
estimates, the photometric strip was then handed to the
patient and healthcare professional to observe and note their
visual estimates individually on a collection form to avoid bias.
Statistical methods
Stata® 12.0 software package (StataCorp, College Station, TX,
USA) and R (R Centre for Statistical Computing, Vienna,
Austria) were used for statistical analysis. For categorical vari-
ables; frequency and percentages were used to describe the
data (Table 1). For continuous variables, the Shapiro–Wilk test
was run with a p-value (p < 0.05) to test normality (Table 2).
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Introduction
Type 2 diabetes mellitus is a met bolic disord r that results in
persistently higher than normal serum glu ose levels in
untreated patie ts.1 Long-term vascular complications r the
cause of poor outcomes, such as death and disability,2 with car-
di vascula disease being the major caus .3 Dyslipidaemia,
whic is an inde endent risk fact r for cardiovascu ar dise se
is pr ent in the majority of p tient with type 2 diabetes and
affects all lipid fractions.4
Elevated total a d LDL cholesterol (LDL-C) as well as elevated
levels of triglycerides together with low levels of HDL cholesterol
(HDL-C) are found in the majority of patients with type 2
diabetes.4
Redu ing LDL-C levels onfers signific nt protection against the
higher risk of cardiovascular and cerebrovascular complication
in dyslipidaemic patients.4 A redu tion in LDL-C by approxi-
mately 1 mmol/l d creases the five-year incidence of major cor-
onary events by approxim t ly 20%.5
HDL-C levels are also used as a marker of cardiovascular disease
risk with low levels being associated with a greater risk of cardi-
ovascular disease, independent of LDL-C levels.6,7
In addition, high triglyceride levels in both fasted and non-fasted
patients are also associated with a greater cardiovascular risk.8
Treatment of diabetic dyslipidaemia with statins (or HMG CoA
reductase inhibitors) has been shown to significantly reduce
adverse ca diovascular events and these are ther fore the
drugs of choice in this setting.2
Several tatins with differing potencies ar curren ly in us . For
example in the Collaborative Atorvastatin Diabetes Study
(CARDS) study a l w dose of atorvastatin (10 mg daily)
decr ased LDL-C by 40% and triglycerides by 19%.9 The Euro
Aspire studies revealed a reduction in total cho esterol levels
greater than 4.5 mmol/l from 94.5% to 46.2% attributable to
stati therapy.10
At maximal dose atorvastatin and rosuvastatin can p tentially
decrease LDL-C by as much as 60%.5
Another class of lipid-l wering th rapy called fibrates (or peroxi-
som prolifer tor-activated receptor-α agonists), in the form of
the drug ezetimibe, may be necessary to red ce LDL-C,
especially in p tients at high risk for car iovascular dise se.11
The role of other treatment options f r this purpose i still
u er investigation.
The combined use of a statin with a fibrate may be more ben-
eficial than statin therapy alone in patients with type 2 diabetes
and dyslipidaemia12 but this has not been clearly demonstrated
in cardiovascular outcome studies.13
Globally, poor control of diabetic dyslipidae ia remains a
problem and an unacceptably low proportion of patients
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Normally distributed continuous data had means reported,
and non-normally distributed data had the median and IQR
reported.
Bland–Altman plots were used to compare glucometer concen-
tration values obtained by a glucometer (true values) with values
obtained by visual matching of reflectance photometric strips to
colorimetric charts. Agreement of values was tested by plotting
the difference between visual estimates and true values against
the mean of true values and visual estimates or the reference
values.
Clarke’s error grid analysis was used to assess the impact on
clinical decisions, if any, of using visual colour matching to esti-
mate blood glucose. Clarke’s error grid is used to classify glucose
measures taken by an alternative method according to their
accuracy with regard to a reference method. In the study the
reference method was the glucometer reading.
Results
Of the 144 patients, 47 (32.6%) were male and 97 (67%) were
female (Table 1). A total of 25 patients were reported to have
complications related to diabetes, 15 of whom had visual com-
plications. In terms of HbA1c, 16 (14.2%) of the patients were
well controlled (HbA1c < 7%), 37 (32.7%) of patients enrolled
had moderately controlled glucose and 60 (53.1%) had poorly
controlled glucose (HbA1c > 10%). A total of 80 (55.6%) of the
patients had type 2 diabetes and 59 (41.0%) had type 1 diabetes.
The Ishihara test identified only one colour-blind patient.
Bland–Altman plots
Bland–Altman plots were used to assess differences between
true blood glucose measures, i.e. measures obtained by a gluc-
ometer, and visual estimates given by patients and healthcare
professionals.
The Bland–Altman plot for patient estimates (Figure 1) had a
mean difference of 0.4 mmol/l (95% CI 1.2−0.5 mmol/l). The
plot had limits of agreement (11.0−10.2 mmol/l), with a bias of
+0.4 mmol/l.
Bland–Altman plots for estimates by healthcare professionals
(Figure 2) had a mean difference of 0.80 mmol/l (95% CI 1.30–
0.31 mmol/l). The estimates of healthcare professionals
had limits of agreement (6.7−5.7 mmol/l), with a bias of
+0.8 mmol/l.
Clarke’s error grid analysis
Zone A had 48 (33.3%) of the total blood glucose estimates by
patients, which meant 33.3% of the total blood glucose esti-
mates were within approximately 20% of the actual blood
glucose. Zone B was the modal zone and had 62 (43.1%) of
the total estimates that were in excess of 20% from the actual
blood glucose but would not result in inappropriate treatment.
Zone C had 20 (13.9%) of the total blood glucose estimates,
which in terms of treatment meant 13.9% of the total esti-
mations would have resulted in an unnecessary treatment
response. Zone D made up nine (6.3%) of the total blood
glucose estimates. Zone E had five (3.5%) of the total blood esti-
mates, which in terms of treatment would have resulted in con-
fusion by the patient on how to respond (Figure 3).
Figure 4 indicates estimates of blood glucose given by health-
care professionals, which had 68 (47.2%) estimates in zone A,
65 (45.1%) in zone B, 5 (3.5%) in zone C and 6 (4.2%) in zone
D. Zone A was the modal zone with 47% of the estimates
being approximately 20% from the actual blood glucose
measure. Zone B had 45.1% of the total estimates, which were
more than approximately 20% from the actual glucose and
would not result in inappropriate treatment. Zone C had 5
(3.5%) of the total estimates; in treatment terms, 3.5% of the esti-
mates would result in inappropriate treatment. Zone D had 6
(4.2%) of the estimates, which would result in potential con-
fusion between hypoglycaemic and hyperglycaemic states.
Discussion
Bland–Altman plots of the difference between patient visual
glucose estimates and true values had limits of agreement of
11.1 to 10.4 mmol/l, while estimates of healthcare professionals
and true values had a limit of agreement of 6.7 to 5.7 mmol/l.
This meant that healthcare professionals gave estimates that
were closer to the true blood glucose measure in comparison
with patient estimates. The mean difference for estimates by
healthcare professionals was 0.8 mmol/l (95% CI 1.30–0.31
mmol/l), while patient estimates had a mean difference of 0.4
mmol/l (95% CI 1.28−0.5 mmol/l). In this study, despite the
Table 2: Summary table of continuous variables
Variable Mean Median IQR SD
Age (n = 142) (years) 50.7 – – 14.3





Left eye 6/12 6/18–6/9 –
Right eye 6/12 6/18–6/9
HbA1c (%)* (n = 113) 10.2 7.9–12.7
Cholesterol (mmol/l)
Total cholesterol (n = 123) 4.1 3.6–4.8
LDL (n = 121) 2.0 1.5–2.6
HDL (n = 123) 1.4 1.0–1.6
Triglycerides (n = 121) 1.5 0.9–2.0
*HbA1c reported as a percentage, with target for diabetes patients as 7%.
Table 1: Descriptive demographics (categorical data)
Variable Summary
Sex (n = 144):
Male 47 (32.6%)
Female 97 (67.4%)
Diabetes type (n = 144):
Type 2 diabetes 80 (55.6%)
Type 1 diabetes 59 (41.0%)
Uncertain 5 (3.4%)
Medication being used to manage diabetes (n = 125):
Insulin 47 (33%)
Oral agents 78 (54%)
Both agents 19 (13%)
Hypertension (n = 137) 97 (70.8%)
Complications (n = 25):
Cataract in one eye 9 (6.3%)
Cataract in both eyes 6 (4.2%)
Diabetic retinopathy 10 (6.9%)
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Normally distributed continuous data had means reported,
and non-normally distributed data had the median and IQR
reported.
Bland–Altman plots were used to compare glucometer concen-
tration values obtained by a glucometer (true values) with values
obtained by visual matching of reflectance photometric strips to
colorimetric charts. Agreement of values was tested by plotting
the difference between visual estimates and true values against
the mean of true values and visual estimates or the reference
values.
Clarke’s error grid analysis was used to assess the impact on
clinical decisions, if any, of using visual colour matching to esti-
mate blood glucose. Clarke’s error grid is used to classify glucose
measures taken by an alternative method according to their
accuracy with regard to a reference method. In the study the
reference method was the glucometer reading.
Results
Of the 144 patients, 47 (32.6%) were male and 97 (67%) were
female (Table 1). A total of 25 patients were reported to have
complications related to diabetes, 15 of whom had visual com-
plications. In terms of HbA1c, 16 (14.2%) of the patients were
well controlled (HbA1c < 7%), 37 (32.7%) of patients enrolled
had moderately controlled glucose and 60 (53.1%) had poorly
controlled glucose (HbA1c > 10%). A total of 80 (55.6%) of the
patients had type 2 diabetes and 59 (41.0%) had type 1 diabetes.
The Ishihara test identified only one colour-blind patient.
Bland–Altman plots
Bland–Altman plots were used to assess differences between
true blood glucose measures, i.e. measures obtained by a gluc-
ometer, and visual estimates given by patients and healthcare
professionals.
The Bland–Altman plot for patient estimates (Figure 1) had a
mean difference of 0.4 mmol/l (95% CI 1.2−0.5 mmol/l). The
plot had limits of agreement (11.0−10.2 mmol/l), with a bias of
+0.4 mmol/l.
Bland–Altman plots for estimates by healthcare professionals
(Figure 2) had a mean difference of 0.80 mmol/l (95% CI 1.30–
0.31 mmol/l). The estimates of healthcare professionals
had limits of agreement (6.7−5.7 mmol/l), with a bias of
+0.8 mmol/l.
Clarke’s error grid analysis
Zone A had 48 (33.3%) of the total blood glucose estimates by
patients, which meant 33.3% of the total blood glucose esti-
mates were within approximately 20% of the actual blood
glucose. Zone B was the modal zone and had 62 (43.1%) of
the total estimates that were in excess of 20% from the actual
blood glucose but would not result in inappropriate treatment.
Zone C had 20 (13.9%) of the total blood glucose estimates,
which in terms of treatment meant 13.9% of the total esti-
mations would have resulted in an unnecessary treatment
response. Zone D made up nine (6.3%) of the total blood
glucose estimates. Zone E had five (3.5%) of the total blood esti-
mates, which in terms of treatment would have resulted in con-
fusion by the patient on how to respond (Figure 3).
Figure 4 indicates estimates of blood glucose given by health-
care professionals, which had 68 (47.2%) estimates in zone A,
65 (45.1%) in zone B, 5 (3.5%) in zone C and 6 (4.2%) in zone
D. Zone A was the modal zone with 47% of the estimates
being approximately 20% from the actual blood glucose
measure. Zone B had 45.1% of the total estimates, which were
more than approximately 20% from the actual glucose and
would not result in inappropriate treatment. Zone C had 5
(3.5%) of the total estimates; in treatment terms, 3.5% of the esti-
mates would result in inappropriate treatment. Zone D had 6
(4.2%) of the estimates, which would result in potential con-
fusion between hypoglycaemic and hyperglycaemic states.
Discussion
Bland–Altman plots of the difference between patient visual
glucose estimates and true values had limits of agreement of
11.1 to 10.4 mmol/l, while estimates of healthcare professionals
and true values had a limit of agreement of 6.7 to 5.7 mmol/l.
This meant that healthcare professionals gave estimates that
were closer to the true blood glucose measure in comparison
with patient estimates. The mean difference for estimates by
healthcare professionals was 0.8 mmol/l (95% CI 1.30–0.31
mmol/l), while patient estimates had a mean difference of 0.4
mmol/l (95% CI 1.28−0.5 mmol/l). In this study, despite the
Table 2: Summary table of continuous variables
Variable Mean Median IQR SD
Age (n = 142) (years) 50.7 – – 14.3





Left eye 6/12 6/18–6/9 –
Right eye 6/12 6/18–6/9
HbA1c (%)* (n = 113) 10.2 7.9–12.7
Cholesterol (mmol/l)
Total cholesterol (n = 123) 4.1 3.6–4.8
LDL (n = 121) 2.0 1.5–2.6
HDL (n = 123) 1.4 1.0–1.6
Triglycerides (n = 121) 1.5 0.9–2.0
*HbA1c reported as a percentage, with target for diabetes patients as 7%.
Table 1: Descriptive demographics (categorical data)
Variable Summary
Sex (n = 144):
Male 47 (32.6%)
Female 97 (67.4%)
Diabetes type (n = 144):
Type 2 diabetes 80 (55.6%)
Type 1 diabetes 59 (41.0%)
Uncertain 5 (3.4%)
Medication being used to manage diabetes (n = 125):
Insulin 47 (33%)
Oral agents 78 (54%)
Both agents 19 (13%)
Hypertension (n = 137) 97 (70.8%)
Complications (n = 25):
Cataract in one eye 9 (6.3%)
Cataract in both eyes 6 (4.2%)
Diabetic retinopathy 10 (6.9%)
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narrower limits of agreement by healthcare professionals, the
95% CI of their mean estimates did not include a mean differ-
ence of zero. This means the visual estimations given by health-
care professionals are not as accurate as glucometer readings.
The positive mean difference in estimates given by both patients
and healthcare professionals indicates a positive bias for visually
estimated glucose. A positive bias on the Bland–Altman plot
arises when the reference method (glucometer reading) is less
than the method under assessment (visual estimation), an indi-
cation of an overestimation by the method under assessment.
For patients the mean difference for estimates had a 95% CI
that included a mean difference of zero. This means visual esti-
mation of glucose by patients may result in glucose readings
closer to that of a glucometer, despite the positive bias.
The Clarke’s error grid analysis (Figures 3 and 4) classified the
estimates into five clinical categories, zones A–E. The estimates
in zone A indicated estimates within 20% of the actual glucose
value. Zone A formed the modal zone for estimates given by
healthcare professionals, with the modal zone for patient esti-
mates being zone B. This meant estimates given by healthcare
professionals were more likely to result in estimates that were
more clinically relevant when compared with patient estimates.
Zone C, which identifies results that would lead to an unnecess-
ary treatment response, had 13.9% and 3.5% of estimates of
patients and healthcare professionals respectively. This meant
for this study, in a clinical setting, patient participants were
more likely to erroneously respond to measurements when
Figure 1: Bland–Altman plot for blood glucose estimates by patients and glucometer readings.
Figure 2: Bland–Altman plot for blood glucose estimates by healthcare professionals and glucometer readings.
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Figure 3: Clarke’s error grid of blood glucose estimates by patients with glucometer readings as reference values. On the right the number of estimates
and percentages in each zone.
Figure 4: Clarke’s error grid of blood glucose estimates by healthcare professionals with glucometer readings as reference. On the right the number of
estimates and percentages in each zone.
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Figure 3: Clarke’s error grid of blood glucose estimates by patients with glucometer readings as reference values. On the right the number of estimates
and percentages in each zone.
Figure 4: Clarke’s error grid of blood glucose estimates by healthcare professionals with glucometer readings as reference. On the right the number of
estimates and percentages in each zone.
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not required in comparison with estimates by healthcare pro-
fessionals. The potential for adverse incidents arising from the
use of visual estimates would have been higher in the patient
estimate group compared with estimates by healthcare pro-
fessionals. This is suggested by the higher ratio of estimates in
zones E and D of patient estimates as compared with zone D
for healthcare professionals.
A similar study by Essack in 2009,1 in which five glucometers
were compared, was performed in South Africa. In their study,
across glucometers proportional bias was observed as the
blood glucose increased, a trend this study observed. Essack’s
study showed differences in blood glucose measures across
devices, differences this study also noted between estimates
by patients and healthcare professionals. The accuracy of the
measures was judged on the ISO guidelines, which stipulate
that, at most, the blood glucose measures should be within
approximately 20% of the true value. For this study, 33.3% of
patient estimates, and 47.2% of estimates by healthcare pro-
fessionals, complied with these guidelines. This meant visual
estimates were consistently higher than the true value, a
finding consistent with a positive bias for all visual estimates.
Limitations
The study sampled a limited number of healthcare professionals
when compared with patients. This meant that, over the course
of the study, healthcare professionals would have gone through
a learning curve as they gave multiple visual estimates an oppor-
tunity that was not afforded to patients participating in the
study.
The colorimetric chart used for estimating blood glucose in
the study made use of six colour shades with corresponding
glucose values on a continuous scale that ranges from 0
mmol/l to > 25 mmol/l. Despite asking patients to estimate
values in between colour shade scale values on the glucose
strip container, both patients and healthcare providers most
commonly selected a value in agreement with the printed
shades. This led to estimated values in discrete bands. The use
of a colorimetric chart with more blood glucose colour code esti-
mates might have improved the results.
Conclusion
Patients are unable to estimate blood glucose by visual esti-
mation when it matters. They will be at risk of overtreating hypo-
glycaemia or inappropriately changing treatment if they use the
visual method of blood glucose monitoring. Healthcare pro-
fessionals are better at visual estimation of blood glucose;
however, they should preferably use a glucose measuring
device in order to properly assess the blood glucose of patients.
The cost of an incorrect blood glucose test may result in inap-
propriate treatment implemented for hypoglycaemia with resul-
tant risk of hospital admission or even hypoglycaemic brain
injury. Inaccurate identification or underestimation of high
blood glucose may result in result in inappropriate adjustment
of treatment with delays in glucose control. The risk of long-
term diabetes complications, and acute hyperglycaemic compli-
cations, which significantly escalate the costs of diabetes man-
agement, may result.
Colorimetric matching in the estimation of blood glucose is
inexact, and its use by patients or healthcare providers should
not be encouraged. Despite visual colour matching being
inexact, healthcare professionals gave visual estimates that
were more accurate in comparison with those of patients.
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